Prelude Therapeutics Incorporated PRLD
3.88
(0.11)
(2.76%)
as of 25 Sep
- Market cap
- $318.4M
- P/E
- 0.0×
Follow PRLD
Insider Buys
alert about insiders buying in the last 12 month
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | — | — | 0.00 | 0.00 |
P/S ratio |
— | — | — | — | — | — | — | 0.00 | 11.66 |
P/FCF ratio |
— | — | — | — | — | — | — | 0.00 | 0.00 |
P/Operating CF |
— | — | — | — | — | — | — | (4.68) | 9.65 |
P/B ratio |
— | — | — | — | — | — | — | 0.74 | 3.25 |
Price to Tangible BV |
— | — | — | — | — | — | — | 0.74 | 3.25 |
EV/Sales |
— | — | — | — | — | — | — | 0.00 | 6.27 |
EV/EBITDA |
— | — | — | — | — | — | — | 0.26 | 0.00 |
EV/Operating CF |
— | — | — | — | — | — | — | 0.36 | (2.13) |
EV/FCF |
— | — | — | — | — | — | — | 0.35 | (2.13) |
Quick Ratio |
— | 6.37 | 3.90 | 19.19 | 15.17 | 9.30 | 10.67 | 5.21 | 1.95 |
Current Ratio |
— | 6.37 | 4.18 | 19.41 | 15.37 | 9.42 | 10.79 | 5.30 | 1.99 |
Net Debt/EBITDA |
— | 1.05 | 0.68 | 3.75 | 2.61 | 1.69 | 1.73 | 0.94 | 1.00 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.08 |
Operating CF/Net income |
— | 0.88 | 0.93 | 0.81 | 0.75 | 0.73 | 0.88 | 0.81 | 0.57 |
Capex/Depreciation |
— | 0.00 | (2.04) | (1.15) | (1.02) | (0.77) | 1.52 | 0.27 | (0.05) |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | 40.72% | 76.47% | (69.95%) | (44.85%) | (47.97%) | (56.33%) | (69.01%) | (99.45%) | |
| — | (178.96%) | (144.06%) | (46.39%) | (42.25%) | (43.93%) | (48.91%) | (56.12%) | (62.81%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (1,989.73%) | 0.00% | 0.00% |
Return on Tangible Assets |
— | (105.17%) | (161.83%) | (26.86%) | (39.91%) | (61.54%) | (55.11%) | (108.68%) | (172.11%) |
Average Days of Receivables |
— | — | — | — | — | — | — | 0.00 | 0.00 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1,685.64% | 776.77% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 410.27% | 184.56% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 304.93% | 98.13% |
Graham Net Nets |
— | — | — | — | — | — | — | 0.95 | 0.15 |
Graham Number |
— | — | — | — | — | — | — | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | — | — | — | (132.03%) | (44.48%) |
Free Cash Flow Yield |
— | — | — | — | — | — | — | (106.82%) | (25.26%) |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.09 | 0.16 |
Operating CF per Share |
— | (0.30) | (15.38) | (3.70) | (1.81) | (1.77) | (1.77) | (1.36) | (0.73) |
Capex per Share |
— | 0.00 | (0.47) | (0.05) | (0.05) | (0.06) | (0.06) | (0.01) | 0.00 |
Free Cash Flow per Share |
— | (0.30) | (15.84) | (3.75) | (1.86) | (1.83) | (1.83) | (1.37) | (0.73) |
Cash per Share |
— | 0.36 | 11.31 | 17.50 | 6.32 | 4.26 | 3.86 | 1.76 | 1.34 |
Shareholders Equity per Share |
— | 0.32 | 10.20 | 17.00 | 6.21 | 4.13 | 3.93 | 1.73 | 0.89 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.32 | 10.20 | 17.00 | 6.21 | 4.13 | 3.93 | 1.73 | 0.89 |
Free Cash Flow |
— | (12.95) | (26.44) | (46.80) | (85.85) | (86.75) | (110.58) | (103.65) | (56.37) |
Working Capital |
— | 13.15 | 15.39 | 209.43 | 275.91 | 182.68 | 213.76 | 110.25 | 52.70 |
Capital Expenditures |
— | (0.53) | (0.78) | (0.62) | (2.32) | (3.02) | (3.51) | (0.76) | (0.07) |
Net Current Asset Value |
— | 13.09 | 15.38 | 209.40 | 275.91 | 179.32 | 195.01 | 91.84 | 33.01 |
EV/EBIT |
— | — | — | — | — | — | — | 0.26 | 0.00 |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.11 | 0.01 |
Net Profit Margin |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (1,816.76%) | (819.59%) |
Price to Operating Income |
— | — | — | — | — | — | — | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.18 | 0.23 | 0.22 | 0.58 | 0.80 | (0.31) | (0.42) | 0.26 |
Cash ROIC |
— | (46.67%) | (76.06%) | (11.30%) | (15.15%) | (22.32%) | (24.34%) | (41.37%) | (35.74%) |
Accounts Receivable Turnover |
— | — | — | — | — | — | — | 0.00 | 0.00 |
Accounts Payable Turnover |
— | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 3,336.44 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Payables |
— | 1.67 | 1.67 | 2.95 | 5.88 | 7.31 | 5.68 | 6.16 | 5.86 |
Average Assets |
— | 8.20 | 19.14 | 122.73 | 264.34 | 262.80 | 249.08 | 226.59 | 158.42 |
Average Common Equity |
— | (36.05) | (36.05) | 81.39 | 249.04 | 240.67 | 216.26 | 184.27 | 100.05 |
Columns are period end dates